TY - JOUR
T1 - Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II)
T2 - Clinical, technical and socio-economic considerations
AU - Aljurf, M.
AU - Weisdorf, D.
AU - Hashmi, S. K.
AU - Nassar, A.
AU - Gluckman, E.
AU - Mohty, M.
AU - Rizzo, D.
AU - Pasquini, M.
AU - Hamadani, M.
AU - Saber, W.
AU - Hari, P.
AU - Kharfan-Dabaja, M.
AU - Majhail, N.
AU - Gerges, U.
AU - Ali Hamidieh, A.
AU - Hussain, F.
AU - Elhaddad, A.
AU - Mahmoud, H. K.
AU - Tbakhi, A.
AU - Othman, T. B.
AU - Hamladji, R. M.
AU - Bekadja, M. A.
AU - Ahmed, P.
AU - Bazarbachi, A.
AU - Adil, S.
AU - Alkindi, S.
AU - Ladeb, S.
AU - Dennison, D.
AU - Patel, M.
AU - Lu, P.
AU - Quessar, A. E.
AU - Okamoto, S.
AU - Atsuta, Y.
AU - Alhejazi, A.
AU - Ayas, M.
AU - Ahmed, S. O.
AU - Novitzky, N.
AU - Srivastava, A.
AU - Seber, A.
AU - Elsolh, H.
AU - Ghavamzadeh, A.
AU - Confer, D.
AU - Kodera, Y.
AU - Greinix, H.
AU - Szer, J.
AU - Horowitz, M.
AU - Niederwieser, D.
N1 - Publisher Copyright:
© 2020 The Authors
PY - 2020/3
Y1 - 2020/3
N2 - The development of hematopoietic stem cell transplantation (HSCT) programs can face significant challenges in most developing countries because such endeavors must compete with other government health care priorities, including the delivery of basic services. While this is may be a limiting factor, these countries should prioritize development of the needed expertise to offer state of the art treatments including transplantation, by providing financial, technological, legal, ethical and other needed support. This would prove beneficial in providing successful programs customized to the needs of their population, and potentially provide long-term cost-savings by circumventing the need for their citizens to seek care abroad. Costs of establishing HSCT program and the costs of the HSCT procedure itself can be substantial barriers in developing countries. Additionally, socioeconomic factors intrinsic to specific countries can influence access to HSCT, patient eligibility for HSCT and timely utilization of HSCT center capabilities. This report describes recommendations from the Worldwide Network for Blood and Marrow Transplantation (WBMT) for establishing HSCT programs with a specific focus on developing countries, and identifies challenges and opportunities for providing this specialized procedure in the resource constrained setting.
AB - The development of hematopoietic stem cell transplantation (HSCT) programs can face significant challenges in most developing countries because such endeavors must compete with other government health care priorities, including the delivery of basic services. While this is may be a limiting factor, these countries should prioritize development of the needed expertise to offer state of the art treatments including transplantation, by providing financial, technological, legal, ethical and other needed support. This would prove beneficial in providing successful programs customized to the needs of their population, and potentially provide long-term cost-savings by circumventing the need for their citizens to seek care abroad. Costs of establishing HSCT program and the costs of the HSCT procedure itself can be substantial barriers in developing countries. Additionally, socioeconomic factors intrinsic to specific countries can influence access to HSCT, patient eligibility for HSCT and timely utilization of HSCT center capabilities. This report describes recommendations from the Worldwide Network for Blood and Marrow Transplantation (WBMT) for establishing HSCT programs with a specific focus on developing countries, and identifies challenges and opportunities for providing this specialized procedure in the resource constrained setting.
KW - Bone marrow transplantation
KW - Developing countries
KW - Low income countries
UR - http://www.scopus.com/inward/record.url?scp=85080069497&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080069497&partnerID=8YFLogxK
U2 - 10.1016/j.hemonc.2019.08.002
DO - 10.1016/j.hemonc.2019.08.002
M3 - Article
C2 - 31449781
AN - SCOPUS:85080069497
SN - 1658-3876
VL - 13
SP - 7
EP - 16
JO - Hematology/ Oncology and Stem Cell Therapy
JF - Hematology/ Oncology and Stem Cell Therapy
IS - 1
ER -